Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
19 drugs in development
By Therapeutic Area
top 6
R&D Momentum
89/100
Pipeline Velocity
65/100
Trial Completion Rate
76/100
Pipeline Concentration
19/100
Pipeline Freshness
69/100
Strategic Signals
Activity
Last 14 days
Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics
Intervening on Women's Health for Rural Young Cancer Survivors
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
Targeting Food Cue Responsiveness for Weight Loss
Accurate Point of Care Liver Disease Diagnostics
"Bupe by the Book": Developing and Testing a Tele-Buprenorphine Intervention in Public Libraries With Unstably Housed Persons With Opioid Use Disorder
Development of a Recovery-Oriented Suicide Prevention Intervention With Peers for Clinical High Risk for Psychosis
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)